Table 1.
Representative and ongoing trials of neoadjuvant immunotherapy or chemoimmunotherapy for resectable NSCLC.
| Trial name/NCT number | Phase | Stage | Treatment | Sample size | MPR | pCR |
|---|---|---|---|---|---|---|
| CheckMate159 (NCT02259621) | I | I‐IIIA | Nivolumab | 22 | 45% | 10% |
| LCMC3 (NCT02927301) | II | IB‐IIIA | Atezolizumab | 101 | 20.4% | 6.8% |
| NEOSTAR (NCT03158129) | II | I‐IIIA | Nivolumab ± ipilimumab | 44 | 24% versus 50% | 10% versus 38% |
| NADIM (NCT03081689) | II | IIIA | Nivolumab + carboplatin/paclitaxel | 46 | 83% | 63% |
| NADIM II (NCT03838159) | II | IIIA | Nivolumab + carboplatin/paclitaxel | 87 | 52% | 36.2% |
| SAKK 16/14 (NCT02572843) | II | IIIA | Durvalumab + cisplatin/docetaxel | 67 | 62% | 18% |
| CheckMate816 (NCT02998528) | III | IB‐IIIA | Nivolumab + platinum‐doublet chemotherapy/platinum‐doublet chemotherapy alone | 358 | 36.9% versus 8.9% | 24% versus 2.2% |
| HCRN LUN17‐321 (NCT03871153) | II | III | Durvalumab + carboplatin/paclitaxel + radiation | 25 | Not reported | Not reported |
| NCT04061590 | II | I‐IIIA | Pembrolizumab + cisplatin/pemetrexed | NA | Not reported | Not reported |
| IMpower030 (NCT03456063) | III | II–IIIB | Atezolizumab + platinum‐based chemotherapy | 453 | Not reported | Not reported |
Abbreviation: NSCLC, non‐small cell lung cancer.